VYNE Therapeutics Inc. Balance Sheet
VYNE|8 years of annual SEC 10-K data (FY2018-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 8 fiscal years. All figures from audited SEC 10-K filings.
VYNE Therapeutics Inc. had $67M in total assets and $89M in shareholders' equity as of FY2025. Total debt was $0 against $20M in cash, resulting in a $20M net cash position.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.19 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $19.9M | $19.9M | $30.6M | $30.9M | $42.3M | $57.6M | $49.5M | $10.2M |
| Accounts Receivable | - | - | - | $173.0K | $7.6M | $15.8M | - | - |
| Inventory | - | - | - | - | - | $7.4M | - | - |
| Current Assets | $64.4M | $64.4M | $96.0M | $38.3M | $63.2M | $87.3M | $78.3M | $139.5M |
| PP&E (Net) | $113.0K | $113.0K | - | - | $354.0K | $555.0K | $98.0K | $146.0K |
| Total Assets | $66.9M | $66.9M | $97.7M | $40.8M | $67.0M | $93.7M | $79.2M | $139.9M |
| Current Liabilities | $14.8M | $14.8M | $7.5M | - | - | $21.5M | $10.7M | $9.5M |
| Total Debt | $0 | - | - | - | - | $33.2M | - | - |
| Shareholders' Equity | $88.7M | $88.7M | $31.2M | $48.6M | $37.5M | $17.6M | -$57.0M | -$29.4M |